Документ не применяется. Подробнее см. Справку

Список литературы

1. Баркаган З.С., Момот А.П. Диагностика и контролируемая терапия нарушений гемостаза. М., 2001.

2. Добровольский А.Б., Косырев А.Б. Протромбиновый тест: Методика выполнения и клиническое значение. Ассоциация медицинской лабораторной диагностики. Информационный бюллетень, 1995; 2: 34 - 38.

3. Момот А.П. Принципы и алгоритмы клинико-лабораторной диагностики. СПб., 2006.

4. Основы клинической гемостазиологии и гемореологии: монография/Под ред. И.Л. Давыдкина, А.П. Момота, Н.И. Зозули, Е.В. Ройтмана. - Самара: ООО ИПК "Самарская Губерния", 2017.

5. Рекомендации Всероссийской ассоциации по изучению тромбозов, геморрагий и патологии сосудов. М., 2002.

6. Руководство по гематологии: в 3 т. Т. 3/Под редакцией А.И. Воробьева. 3-е изд. М., 2005.

7. Суворова А.В., Абраменко Л.И., Курденко И.В., Назарова Р.В. Патология системы гемостаза у новорожденных. Барнаул, 2004.

8. Шабалов Н.П. Гемостаз в динамике первой недели жизни как отражение механизмов адаптации к внеутробной жизни новорожденных. Педиатрия, 2000; 3: 84 - 91.

9. Acharya, S.S., Coughlin, A., Dimichele, D.M. & North American Rare Bleeding Disorder Study, G. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. Journal of Thrombosis and Haemostasis, 2004; 2: 248 - 256.

10. Akhavan, S., Mannucci, P.M., Lak, M., Mancuso, G., Mazzucconi, M.G., Rocino, A., Jenkins, P.V. & Perkins, S.J. Identification and three-dimensional structural analysis of nine novel mutations in patients with prothrombin deficiency. Thrombosis and Haemostasis, 2000; 84: 989 - 997.

11. Andrew D. Mamford, Writing Group Chair and BCSH Task Force Member Sam Ackroyd, Raza Alikhan, Louise Bowles, Pratima Chowdary, John Grainger, Jason Mainwaring, Mary Mathias and Niamh O'Connell on behalf of the BCSH Committee. Guideline for the diagnosis and management of the rare coagulation disorders. British Journal of Haematology 2014; 5: 1 - 23.

12. Baumann Kreuziger, L.M., Morton, C.T. & Reding, M.T. Is prophylaxis required for delivery in women with factor VII deficiency. Haemophilia, 2013; 19: 827 - 832.

13. Beksac, M.S., Atak, Z. & Ozlu, T. Severe factor X deficiency in a twin pregnancy. Archives of Gynecology and Obstetrics, 2010; 281: 151 - 152.

14. Bernardi, F., Dolce, A., Pinotti M., Shapiro, A.D., Santagostino, E., Peyvandi, F., Batorova, A., Lapecorella, M., Schved, J.F., Ingerslev, J., Mariani, G. & International Factor VII Deficiency Study Group. Major differences in bleeding symptoms between factor VII deficiency and hemophilia B. Journal of Thrombosis and Haemostasis, 2009; 7: 774 - 779.

15. Berrettini, M., Mariani, G., Schiavoni, M., Rocino, A., Di Paolantonio, T., Longo, G. & Morfini, M. Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency. Haematologica, 2001; 86: 640 - 645.

16. Bolton-Maggs, P.H., Perry, D.J., Chalmers, E.A., Parapia, L.A., Wilde, J.T., Williams, M.D., Collins, P.W., Kitchen, S., Dolan, G. & Mumford, A.D. The rare coagulation disorders - review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia, 2004; 10: 593 - 628.

17. Bowles, L., Baker, K., Khair, K., Mathias, M. & Liesner, R. Prophylaxis with prothrombin complex concentrate in four children with severe congenital factor X deficiency. Haemophilia, 2009; 15: 401 - 403.

18. Brown, D.L. & Kouides, P.A. Diagnosis and treatment of inherited factor X deficiency. Haemophilia, 2008; 14: 1176 - 1182.

19. Di Minno, M.N., Dolce, A., Mariani, G. & STER Study Group. Bleeding symptoms at disease presentation and prediction of ensuing bleeding in inherited FVII deficiency. Thrombosis and Haemostasis, 2013; 109: 1051 - 1059.

20. Giansily-Blaizot, M., Marty, S., Chen, S.W., Pellequer, J.L. & Schved, J.F. Is the coexistence of thromboembolic events and Factor VII deficiency fortuitous? Thrombosis Research, 2012; 130: S47 - S49.

21. Girolami, A., Vettore, S., Scarparo, P. & Lombardi, A.M. Persistent validity of a classification of congenital factor X defects based on clotting, chromogenic and immunological assays even in the molecular biology era. Haemophilia, 2011; 17: 17 - 20.

22. Girolami, A., Scarparo, P., Bonamigo, E., Treleani, M. & Lombardi, A.M. Homozygous FVII deficiencies with different reactivity towards tissue thromboplastins of different origin. Hematology, 2012; 17: 350 - 354.

23. Herrmann F.H., Auerswald G., Ruiz-Saez A., Navarrete M., Pollmann H., Lopaciuk S., Batorova A., Wulff K. & Greifswald Factor X Deficiency Study Group. Factor X deficiency: clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene. Haemophilia, 2006; 12: 479 - 489.

24. Herrmann, F.H., Wulff, K., Auerswald, G., Schulman, S., Astermark, J., Batorova, A., Kreuz, W., Pollmann, H., Ruiz-Saez, A., De Bosch, N., Salazar-Sanchez, L. & Greifswald Factor VII Deficiency Study Group. Factor VII deficiency: clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene. Haemophilia, 2009; 15: 267 - 280.

25. Kadir, R., Chi, C. & BoltonMaggs, P. Pregnancy and rare bleeding disorders. Haemophilia, 2009; 15: 990 - 1005.

26. Karimi, M., Vafafar, A., Haghpanah, S., Payandeh, M., Eshghi P., Hoofar, H., Afrasiabi, A., Gerdabi, J., Ardeshiri, R., Menegatti, M. & Peyvandi, F. Efficacy of prophylaxis and genotype-phenotype correlation in patients with severe Factor X deficiency in Iran. Haemophilia, 2012; 18: 211 - 215.

27. Keeling, D., Tait, C. & Makris, M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia, 2008; 14: 671 - 684.

28. Kouides, P.A. & Kulzer, L. Prophylactic treatment of severe factor X deficiency with prothrombin complex concentrate. Haemophilia, 2001; 7: 220 - 223.

29. Kulkarni, A.A., Lee, C.A. & Kadir, R.A. Pregnancy in women with congenital factor VII deficiency. Haemophilia, 2006; 12: 413 - 416.

30. Lancellotti, S., Basso, M. & De Cristofaro, R. Congenital prothrombin deficiency: an update. Seminars in Thrombosis and Hemostasis, 2013; 39: 596 - 606.

31. Mannucci, P.M., Duga, S. & Peyvandi, F. Recessively inherited coagulation disorders. Blood, 2004; 104: 1243 - 1252.

32. Mariani, G., Herrmann, F.H., Dolce, A., Batorova, A., Etro, D., Peyvandi, F., Wulff, K., Schved, J.F., Auerswald, G., Ingerslev, J. & Bernardi, F. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thrombosis and Haemostasis, 2005; 93: 481 - 487.

33. Mariani G., Konkle B.A. & Ingerslev J. Congenital factor VII deficiency: therapy with recombinant activated factor VII - a critical appraisal. Haemophilia, 2006; 12: 19 - 27.

34. Mariani, G., Dolce, A., Batorova, A., Auerswald, G., Schved, J.F., Siragusa, S., Napolitano, M., Knudsen, J.B. & Ingerslev, J. Recombinant, activated factor VII for surgery in factor VII deficiency: a prospective evaluation - the surgical STER. British Journal of Haematology, 2011; 152: 340 - 346.

35. Mariani, G., Napolitano, M., Dolce, A., Perez Garrido, R., Batorova, A., Karimi, M., Platokouki, H., Auerswald, G., Bertrand, A.M., Di Minno, G., Schved, J.F., Bjerre, J., Ingerslev, J., Sorensen, B., Ruiz-Saez, A., Seven Treatment Evaluation R. & International Factor V.I.I.D.S.G. Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation. Thrombosis and Haemostasis, 2013; 109: 238 - 247.

36. McMahon, C., Smith, J., Goonan, C., Byrne, M. & Smith, O.P. The role of primary prophylactic factor replacement therapy in children with severe factor X deficiency. British Journal of Haematology, 2002; 119: 789 - 791.

37. Napolitano, M., Giansily-Blaizot, M., Dolce, A., Schved, J.F., Auerswald, G., Ingerslev, J., Bjerre, J., Altisent, C., Charoenkwan, P., Michaels, L., Chuansumrit, A., Di Minno, G., Caliskan, U. & Mariani, G. Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). Haematologica, 2013; 98: 538 - 544.

38. Peyvandi, F., Palla, R., Menegatti, M., Siboni, S.M., Halimeh, S., Faeser, B., Pergantou, H., Platokouki, H., Giangrande, P., Peerlinck, K., Celkan, T., Ozdemir, N., Bidlingmaier, C., Ingerslev, J., Giansily-Blaizot, M., Schved, J.F., Gilmore, R., Gadisseur, A., Benedik-Dolnicar, M., Kitanovski, L., Mikovic, D., Musallam, K.M. & Rosendaal, F.R. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. Journal of Thrombosis and Haemostasis, 2012; 10: 615 - 621.

39. Peyvandi, F., Di Michele, D., Bolton-Maggs, P.H., Lee, C.A., Tripodi, A., Srivastava, A. & Project on Consensus Definitions in Rare Bleeeding Disorders of the Factor VIII/Factor IX Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. Journal of Thrombosis and Haemostasis, 2012; 10: 1938 - 1943.

40. Todd, T. & Perry, D.J. A review of long-term prophylaxis in the rare inherited coagulation factor deficiencies. Haemophilia, 2010; 16: 569 - 583.

41. Uprichard, J. & Perry, D.J. Factor X deficiency. Blood Reviews, 2002; 16: 97 - 110.

42. van Veen J.J., Hampton, K.K., Maclean, R., Fairlie, F. & Makris, M. Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy. Blood Transfusion, 2007; 5: 204 - 209.

43. Viswabandya, A., Baidya, S., Nair, S.C., Abraham, A., George, B., Mathews, V., Chandy, M. & Srivastava, A. Correlating clinical manifestations with factor levels in rare bleeding disorders: a report from Southern India. Haemophilia, 2012; 18: e195 - e200.